Alexander Drilon, MD, on ROS1 Fusion–Positive NSCLC: Efficacy of Zidesamtinib
Alexander Drilon, MD, presents findings from the phase I/II ARROS-1 trial, which investigated the safety and efficacy of zidesamtinib—an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing—in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) who experienced disease progression after previous treatment with a TKI (Abstract PL02.15).